Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy

Acta Ophthalmologica

Volumn 87, Issue 7, 2009, Pages 736-740

  Jiang, Yanrong ^a   Liang, Xiaoying ^a   Li, Xiaoxin ^a   Tao, Yong ^a   Wang, Kai ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Avastin; Clinical efficacy; Intravitreal bevacizumab; Iris neovascularization; Proliferative diabetic retinopathy; Vascular endothelial growth factor; VEGF antibody

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; IRIS DISEASE; MALE; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; INJECTION; IRIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; TREATMENT OUTCOME; VASCULARIZATION; VERY ELDERLY; VITREOUS BODY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; IRIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 72349092733     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2008.01353.x     Document Type: Article

References (17)

1. Avery RL (2006 Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26 : 352 354.
2. Avery RL, Pearlman J, Pieramici DJ et al. (2006 Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 : 1695 1705.
3. Connolly DT, Olander JV, Heuvelman D et al. (1989 Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264 : 20017 20024.
4. Davidorf FH, Mouser JG Derick RJ (2006 Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 26 : 354 356.
5. Ehrenberg M, McCuen BW, Schindler RH et al. (1984 Rubeosis iridis: preoperative iris fluorescein angiography and periocular steroids. Ophthalmology 91 : 321 325.
6. Ferrara N Henzel WJ (1989 Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161 : 851 858.
7. Ferrara N, Hillan KJ Novotny W (2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 29 : 328 335.
8. Grisanti S, Biester S, Peters S et al. (2006 Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142 : 158 160.
9. Kim KJ, Li B, Winer J et al. (1993 Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature 362 : 841 844.
10. Lee P, Wang CC Adamis AP (1998 Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43 : 245 269.
11. Presta LG, Chen H, O' Connor SJ et al. (1997 Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 : 4593 4599.
12. Rodrigo J, Rogrio A, Daniela C et al. (2006 Intravitreal bevacizumab (avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26 : 1006 1013.
13. Rosenfeld PJ (2006 Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 142 : 141 143.
14. Ryan M, Philip J, Carmen A et al. (2006 Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular agerelated macular degeneration. Retina 26 : 495 511.
15. Senger DR, Galli SJ, Dvorak AM et al. (1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 : 983 985.
16. Shima DT, Gougos A, Miller JW et al. (1996 Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 37 : 1334 1340.
17. Teich SA Walsh JB (1981 A grading system for iris neovascularization. Prognostic implications for treatment. Ophthalmology 88 : 1102 1106.